Global Nasal Polyps Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Nasal Polyps treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including AnaptysBio Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Idorsia Pharmaceutical Ltd, Kyowa Hakko Kirin Co Ltd and others.
A Significant contribution to the Nasal Polyps pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Nasal Polyps pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Nasal Polyps condition and increased access to investments is encouraging growth of Nasal Polyps drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Nasal Polyps drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Nasal Polyps therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Nasal Polyps pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Nasal Polyps. Further, orphan drug status, fast track designation, grants awarded and other special status for Nasal Polyps pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Nasal Polyps pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Nasal Polyps Pipeline candidates-
A Significant contribution to the Nasal Polyps pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Nasal Polyps pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Nasal Polyps condition and increased access to investments is encouraging growth of Nasal Polyps drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Nasal Polyps drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Nasal Polyps therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Nasal Polyps pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Nasal Polyps. Further, orphan drug status, fast track designation, grants awarded and other special status for Nasal Polyps pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Nasal Polyps pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Nasal Polyps Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Nasal Polyps drugs
- Late phase: Phase 3 and in-approval Nasal Polyps drugs
- Company overview
- Snapshot
- Nasal Polyps therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Nasal Polyps- Disease Overview
2.2 Nasal Polyps- Pipeline Snapshot
2.3 Nasal Polyps- Pipeline Drugs by Phase
2.4 Nasal Polyps- Pipeline Drugs by Company
2.5 Nasal Polyps- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AnaptysBio Inc Nasal Polyps Drug Pipeline, H2- 2019
3.2 F. Hoffmann-La Roche Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.3 GlaxoSmithKline Plc Nasal Polyps Drug Pipeline, H2- 2019
3.4 Idorsia Pharmaceutical Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.5 Kyowa Hakko Kirin Co Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.6 Novartis AG Nasal Polyps Drug Pipeline, H2- 2019
3.7 OptiNose US Inc Nasal Polyps Drug Pipeline, H2- 2019
3.8 Pfizer Inc Nasal Polyps Drug Pipeline, H2- 2019
3.9 Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Nasal Polyps- Phase 1 Drug Details
4.2 Nasal Polyps- Phase 1 Drug Overview
4.3 Nasal Polyps- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Nasal Polyps- Phase 2 Drug Details
5.2 Nasal Polyps- Phase 2 Drug Overview
5.3 Nasal Polyps- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Nasal Polyps- Phase 3 Drug Details
6.2 Nasal Polyps- Phase 3 Drug Overview
6.3 Nasal Polyps- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Nasal Polyps- Pre-clinical Phase Drug Details
7.2 Nasal Polyps- Pre-clinical Phase Drug Overview
7.3 Nasal Polyps- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Nasal Polyps- Disease Overview
2.2 Nasal Polyps- Pipeline Snapshot
2.3 Nasal Polyps- Pipeline Drugs by Phase
2.4 Nasal Polyps- Pipeline Drugs by Company
2.5 Nasal Polyps- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AnaptysBio Inc Nasal Polyps Drug Pipeline, H2- 2019
3.2 F. Hoffmann-La Roche Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.3 GlaxoSmithKline Plc Nasal Polyps Drug Pipeline, H2- 2019
3.4 Idorsia Pharmaceutical Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.5 Kyowa Hakko Kirin Co Ltd Nasal Polyps Drug Pipeline, H2- 2019
3.6 Novartis AG Nasal Polyps Drug Pipeline, H2- 2019
3.7 OptiNose US Inc Nasal Polyps Drug Pipeline, H2- 2019
3.8 Pfizer Inc Nasal Polyps Drug Pipeline, H2- 2019
3.9 Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Nasal Polyps- Phase 1 Drug Details
4.2 Nasal Polyps- Phase 1 Drug Overview
4.3 Nasal Polyps- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Nasal Polyps- Phase 2 Drug Details
5.2 Nasal Polyps- Phase 2 Drug Overview
5.3 Nasal Polyps- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Nasal Polyps- Phase 3 Drug Details
6.2 Nasal Polyps- Phase 3 Drug Overview
6.3 Nasal Polyps- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Nasal Polyps- Pre-clinical Phase Drug Details
7.2 Nasal Polyps- Pre-clinical Phase Drug Overview
7.3 Nasal Polyps- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
